Hikma Pharmaceuticals Plc Hikma announces licensing agreement with Takeda
August 17 2017 - 2:01AM
RNS Non-Regulatory
TIDMHIK
Hikma Pharmaceuticals Plc
17 August 2017
PRESS RELEASE
Hikma announces new licensing agreement with Takeda for products
in the Middle East and North Africa
-- Enhances MENA product offering in strategic therapeutic areas
-- Reinforces commitment to provide high-quality medicines to patients
London, 17 August 2017 - Hikma Pharmaceuticals PLC (Hikma) (LSE:
HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the multinational
pharmaceutical group, today announces that through its wholly owned
subsidiary Hikma Pharmaceuticals LLC, it has agreed to expand its
licensing and distribution agreement with Takeda Pharmaceutical
Company Limited (Takeda), a global, research and development-driven
pharmaceutical company, adding new products to its portfolio in the
Middle East and North Africa (MENA).
Mazen Darwazah, Vice Chairman and CEO of MENA and Emerging
Markets said, "Our large sales and marketing teams, with particular
expertise in promoting cardiovascular and diabetes treatments, are
well positioned to drive patient access for Takeda's products. We
are pleased to be building on our partnership with Takeda to bring
important medicines to the MENA region. By working with global
partners we are strengthening our product portfolio in growing
therapeutic areas and reinforcing our commitment to improving
patient access to quality medicines."
Danilo Cassani, Vice President and Area Head Near East, Middle
East & Africa added, "At Takeda, we put patients at the centre
of everything we do. As such, our partnership with Hikma is a
testament of our commitment to offer patients world-class
cardiovascular and metabolism (CVM) medicines while keeping focus
on our core therapeutic areas of oncology and gastroenterology.
This will help better serve the unmet medical needs of
patients."
Under the terms of the agreement:
-- Hikma has been granted the exclusive rights
to manufacture and commercialise three of Takeda's
leading primary care product families - Vipedia(TM)
(alogliptin), including Vipdomet(TM) (alogliptin/metformin)
and Incresync(TM) (alogliptin/pioglitazone)
(anti-diabetic), Edarbi(TM) (azilsartan), including
Edarbyclor(TM) (azilsartan/chlorothalidone)
(anti-hypertensive) and Xefo(TM) (lornoxicam)
in its rapid form (anti-inflammatory/ pain)
- in its MENA markets1
-- Hikma has also been granted the exclusive rights
to manufacture and commercialise Takeda's Dexilant(TM)
(dexlansoprozole) (gastric acid secretion inhibitor)
in its MENA markets, with the exception of Saudi
Arabia, UAE and Egypt
-- Hikma's existing license agreement with Takeda
in respect of Xefo(TM) (lornoxicam) tablets
(anti-inflammatory/ pain), has been expanded
beyond Saudi Arabia and Jordan to cover Hikma's
other MENA markets
The new agreement builds on a long-standing strategic
partnership between Hikma and Takeda. The relationship leverages
Hikma's substantial sales and manufacturing presence in MENA and
extensive experience of building brands in the region.
(1) The agreement does not include the Egyptian market for
Vipedia(TM)
-- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Susan VP Corporate Strategy +44 (0)20 7399 2760/
Ringdal and Investor Relations +44 7776 477050
Lucinda Deputy Director of Investor +44 (0)20 7399 2765/
Baker Relations +44 7818 060211
FTI Consulting
Ben Atwell/ Brett Pollard +44 (0)20 3727 1000
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma operates through three businesses: 'Injectables,' 'Generics'
and 'Branded, based principally in the United States, the Middle
East and North Africa (MENA) and Europe. In 2016, Hikma achieved
revenue of $1,950 million and profit attributable to shareholders
of $155 million. For more information visit www.hikma.com.
About Takeda
Takeda Pharmaceutical Company Limited is a global, research and
development-driven pharmaceutical company committed to bringing
better health and a brighter future to patients by translating
science into life-changing medicines. Takeda focuses its R&D
efforts on oncology, gastroenterology and central nervous system
therapeutic areas plus vaccines. Takeda conducts R&D both
internally and with partners to stay at the leading edge of
innovation. New innovative products, especially in oncology and
gastroenterology, as well as our presence in Emerging Markets, fuel
the growth of Takeda. More than 30,000 Takeda employees are
committed to improving quality of life for patients, working with
our partners in health care in more than 70 countries. For more
information, visit http://www.takeda.com/news.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADMGMRFVFGNZZ
(END) Dow Jones Newswires
August 17, 2017 02:01 ET (06:01 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024